Patients should be counseled that gastrointestinal symptoms usually do not indicate treatment failure and often resolve with continued therapy
Beyond their role in weight reduction, which itself can lessen mechanical friction and inflammation in intertriginous areas, GLP-1s improve insulin sensitivity, cardiometabolic risk factors, and may reduce systemic inflammationall of which can be more prevalent in HS patients
In the first head-to-head trial, tirzepatide reached 20.2% average weight loss vs 13.7% for semaglutide over 72 weeks
Zaragosi LE, Wdziekonski B, Villageois P, Keophiphath M, Maumus M, Tchkonia T, Bourlier V, Mohsen-Kanson T, Ladoux A, Elabd C, Scheideler M, Trajanoski Z, Takashima Y, Amri EZ, Lacasa D, Sengenes C, Ailhaud G, Clement K, Bouloumie A, Dani C
- Gip lm m thm nm, i mi, tn nhang v cc khuyt im da khng u mu
RA Comorbidities, Such as Heart Disease Karacabeyli and colleagues have conducted a study (submitted for publication but not yet published) comparing GLP-1 medications with another diabetes treatment in people with immune-mediated diseases, including RA
